<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03856853</url>
  </required_header>
  <id_info>
    <org_study_id>GNI-F647-1701</org_study_id>
    <nct_id>NCT03856853</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Pirfenidone in Patient With Systemic Sclerosis-associated Interstitial Lung Disease</brief_title>
  <official_title>A Phase III, Randomized, Double-blind, Placebo Controlled, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Pirfenidone in Subjects With Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Continent Pharmaceutical Co, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Genomics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>GNI-EPS Pharmaceuticals, Inc. (GNI Group)</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Continent Pharmaceutical Co, Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the eEfficacy and safety of pirfenidone in subjects
      with systemic sclerosis-associated interstitial lung disease (SSc-ILD)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2018</start_date>
  <completion_date type="Anticipated">May 10, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 10, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative change from baseline (%) of FVC%</measure>
    <time_frame>52 Weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Systemic Sclerosis-associated Interstitial Lung Disease (Ssc-ild)</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pirfenidone group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirfenidone</intervention_name>
    <description>pirfenidone for SSc-ILD treatment</description>
    <arm_group_label>treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>as control</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.Female or male subjects aged between 18 and 75 years of age. 2.2013 ACR / EULAR
        classification criteria for SSc fulfilled. 3.SSc disease onset (defined by first
        non-Raynaud symptom) within 5 years. 4.SSc related Interstitial Lung Disease confirmed by
        HRCT. 5.Forced vital capacity (FVC) 40% to 70% predicted(include 40% and70% ). 6.Subject
        have the ability to understand and sign the informed consent before the trials.

        Exclusion Criteria:

          1. Subjects not fulfill all of the above inclusion criteria.

          2. AST, ALT &gt;1.5 x ULN.

          3. Bilirubin &gt;1.5 x ULN.

          4. Creatinine clearance &lt;30 mL/min.

          5. Airway obstruction (pre-bronchodilator FEV1/FVC &lt;0.7).

          6. Other clinically significant pulmonary abnormalities.

          7. Allergic to test drugs or components (e.g. lactose).

          8. Clinical Significant Pulmonary hypertension:.

               1. Significant past clinical evidence or echocardiography of right heart failure.

               2. History of right heart catheterization showed that cardiac index ≤ 2 l/min/m2.

               3. Pulmonary hypertension, which needs to use EPoprostenol/ Treprostinil for
                  parenteral treatment .

          9. Cardiovascular diseases:

               1. Six weeks in severe hypertension, and out of control after
                  treatment(≥160/100mmHg).

               2. Myocardial infarction within six months.

               3. A period of 6 months in unstable angina.

         10. More than 3 digital fingertip ulcers or a history of severe digital necrosis requiring
             hospitalization or severe other ulcers.

         11. Bleeding risk, including the following criterias:

             a. Predisposition to bleeding. b.Subjects need to the following treatments:
             i.Fibrinolysis, full-dose anticoagulation therapy(such as vitamin K antagonists,
             direct thrombin inhibitor, heparin, Hirudin ).

             ii. High dose antiplatelet therapy[Note: not prohibited to maintain equipment needed
             indwelling venous pathway prophylactic low dose of heparin or heparin fluid (e.g.
             enoxaparin, daily 4000 I.U. s.c.) and the prevention of the use of antiplatelet
             therapy (e.g. acetylsalicylic acid, until 325 mg/d, or other antiplatelet dose of 75
             mg/d the same dose of clopidogrel, or treatment)].

             c.history of hemorrhagic central nervous system (CNS) event within last year. d. Any
             of the following conditions within 3 months: i.Hemoptysis or hematuria ii. Active
             gastrointestinal bleeding or gastrointestinal ulcer. iii. major trauma or major
             surgery (researchers determined). e.coagulation parameters:international normalised
             ratio (INR) &gt;2, prolongation of prothrombin time (PT) and partial thromboplastin time
             (PTT) by &gt;1.5 x ULN)

         12. May interfere with detection procedures (such as interrupt oxygen intolerance in
             pulmonary function tests) or based on the researchers estimate, may affect the test to
             participate in or participate in the test may put patients at risk of disease or other
             complications (such as caused by SSc severe gastrointestinal symptoms).

         13. Researchers determined that life expectancy was due to other diseases (non SSc) for a
             period of up to 2.5 years.

         14. Clinical signs of malabsorption or needing parenteral nutrition.

         15. History of thrombotic event within last year(Including stroke and transient ischemic
             attack).

         16. Previous treatment with nintedanib or pirfenidone.

         17. Use the following medicine:

               1. Treatment with prednisone &gt;10 mg/day within 2 weeks.

               2. Treatment with azathioprine, hydroxychloroquine, colchizine, D-penicillamine,
                  sulfasalazine within 8 weeks .

               3. Treatment with cyclophosphamide, rituximab, tocilizumab, abatacept, leflunomide,
                  tacrolimus, newer anti-arthritic treatments like tofacitinib and ciclosporine A,
                  potassium para-aminobenzoate within 6 months.

         18. Unstable background therapy with cyclophosphamide or mycophenolate mofetil / sodium or
             methotrexate (not allow treatment). Patients must or A. patients cannot receive
             immunosuppressive therapy, sodium cyclophosphamide or mycophenolate mofetil / or MTX
             stable or B. within 6 months of acceptance, and in at least 6 months after
             randomization, the treatment to keep the background stable (exclusion criteria 16 and
             17 and the combined use of early precautions).

         19. Previous or planned hematopoietic stem cell transplantation next year.

         20. Major surgery is planned during the treatment period.

         21. Pregnancy or lactation or make a schedule during the trials.

         22. Give the drug 28 days before or after administration of the 3 month period, women of
             childbearing age * are unwilling or unable to use contraceptive methods highly
             effective (according to ICH M3 (R2)), a highly effective means in the correct and
             consistent application of a barrier method when the failure rate of less than 1% per
             year. * women of childbearing age is defined has undergone menarche and in line with
             &quot;infertile women&quot; standard &quot;[female infertile women&quot; is defined as: postmenopausal
             period (12 months without menstruation, no other medical reasons) or permanent
             sterilization (e.g., tubal occlusion, hysterectomy, bilateral ovarian resection or
             bilateral tubal resection women)].

        (23)According to the researchers,exhibited evidence of alcohol or drug abuse. (24)Patients
        who were unable to understand or comply with the procedure were included in the
        self-administered questionnaire, which was completed without help.

        25.Patients with underlying chronic liver disease (Child Pugh A, B, C hepatic impairment).

        26.Clinical signs of malabsorption or needing parenteral nutrition. 27.With active peptic
        ulcer. 28.With mental illness . 29.Within 3 months to participate in other clinical trials.
        30.Researchers determined that they did not participate in the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Zhang, Ling</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100102</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ling Zhang</last_name>
      <phone>+86-13501209210</phone>
      <email>rlzhang1006@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Qian Wang</last_name>
      <phone>+86-13681211155</phone>
      <email>zhengaqian@icloud.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 26, 2019</study_first_submitted>
  <study_first_submitted_qc>February 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2019</study_first_posted>
  <last_update_submitted>February 26, 2019</last_update_submitted>
  <last_update_submitted_qc>February 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pirfenidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

